Literature DB >> 89089

Antigenic specificity of neutralizing antibody to cholera toxin.

J W Peterson, K E Hejtmancik, D E Markel, J P Craig, A Kurosky.   

Abstract

Selected rabbit antisera to cholera toxin antigens and convalescent cholera patient sera were analyzed using the permeability factor neutralization test and two sensitive in vitro serological assays specific for cholera toxin, cholera toxin A subunit, and cholera toxin B subunit. The results indicated that antisera to cholera toxin contained toxin-neutralizing activity as well as antibodies specific for both the A subunit and B subunit. It was clearly established that antisera to B subunit, devoid of significant anti-A subunit activity, neutralized the vascular permeability activity of cholera toxin. Antisera to A subunit contained neutralizing antibodies and antibodies to both A and B subunits. Absorption with B subunit removed both the toxin-neutralizing and anti-B subunit activities, while the anti-A activity was unaffected. Neutralizing antibody titers of rabbits immunized with B subunit were also observed to be significantly higher than neutralizing antibody titers of sera from A subunit-immunized rabbits, despite the overall similarity in anti-B subunit titers as determined by passive hemagglutination and radioimmunoassay of sera from the two groups of rabbits. Anti-alpha chain sera neither neutralized cholera toxin nor possessed significant antitoxin or anti-B subunit titers as determined by passive hemagglutination and radioimmunoassay. The anti-alpha chain sera contained high levels of antibody specific for A subunit, which is consistent with the hypothesis that the alpha chain is part of the A subunit structure. In contrast, the gamma chain was not shown to be antigenic. Sera from convalescent cholera patients possessed toxin-neutralizing antibody as well as passive hemagglutination and radioimmunoassay antibody against both A and B subunits.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 89089      PMCID: PMC414373          DOI: 10.1128/iai.24.3.774-779.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  7 in total

1.  Covalent structure of the beta chain of cholera enterotoxin.

Authors:  A Kurosky; D E Markel; J W Peterson
Journal:  J Biol Chem       Date:  1977-10-25       Impact factor: 5.157

2.  Structure, function, and antigenicity of cholera toxin.

Authors:  D E Markel; K E Hejtmancik; J W Peterson; A Kurosky
Journal:  J Supramol Struct       Date:  1979

3.  Development of improved cholera vaccine based on subunit toxoid.

Authors:  J Holmgren; A M Svennerholm; I Lönnroth; M Fall-Persson; B Markman; H Lundbeck
Journal:  Nature       Date:  1977-10-13       Impact factor: 49.962

4.  Development of a purified cholera toxoid. II. Preparation of a stable, antigenic toxoid by reaction of purified toxin with glutaraldehyde.

Authors:  R S Rappaport; G Bonde; T McCann; B A Rubin; H Tint
Journal:  Infect Immun       Date:  1974-02       Impact factor: 3.441

5.  A permeability factor (toxin) found in cholera stools and culture filtrates and its neutralization by convalescent cholera sera.

Authors:  J P Craig
Journal:  Nature       Date:  1965-08-07       Impact factor: 49.962

6.  In vitro detection of antibody to cholera enterotoxin in cholera patients and laboratory animals.

Authors:  R A Finkelstein; J W Peterson
Journal:  Infect Immun       Date:  1970-01       Impact factor: 3.441

7.  Radioimmunoassay for the antigenic determinants of cholera toxin and its components.

Authors:  K E Hejtmancik; J W Peterson; D E Markel; A Kurosky
Journal:  Infect Immun       Date:  1977-09       Impact factor: 3.441

  7 in total
  22 in total

1.  Cloning and expression of the Salmonella enterotoxin gene.

Authors:  A K Chopra; C W Houston; J W Peterson; R Prasad; J J Mekalanos
Journal:  J Bacteriol       Date:  1987-11       Impact factor: 3.490

2.  Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin.

Authors:  L de Haan; W R Verweij; I K Feil; T H Lijnema; W G Hol; E Agsteribbe; J Wilschut
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

3.  Protection against experimental cholera by oral or parenteral immunization.

Authors:  J W Peterson
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

4.  Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit.

Authors:  M R Fontana; R Manetti; V Giannelli; C Magagnoli; A Marchini; R Olivieri; M Domenighini; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

Review 5.  Cholera.

Authors:  J B Kaper; J G Morris; M M Levine
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

6.  Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes.

Authors:  A M Svennerholm; L Gothefors; D A Sack; P K Bardhan; J Holmgren
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

7.  Mechanism of action of choleragen and E. coli heat-labile enterotoxin: activation of adenylate cyclase by ADP-ribosylation.

Authors:  J Moss; M Vaughan
Journal:  Mol Cell Biochem       Date:  1981-07-07       Impact factor: 3.396

Review 8.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

9.  Influence of route of administration on immediate and extended protection in rats immunized with Escherichia coli heart-labile enterotoxin.

Authors:  F A Klipstein; R F Engert
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

10.  Lincomycin increases synthetic rate and periplasmic pool size for cholera toxin.

Authors:  M H Levner; C Urbano; B A Rubin
Journal:  J Bacteriol       Date:  1980-07       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.